secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001356576-25-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint
------------------------------------------------------------------------------

- Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).
- Qelbree net sales $81.4M (+31% YoY); GOCOVRI $40.8M (+15% YoY).
- ONAPGO net sales $6.8M in first full quarter; supply constraint pauses new patient starts.
- ZURZUVAE collab revenue $20.2M (post Sage acquisition); Q3 U.S. sales up ~150% YoY.
- Full-year 2025 revenue guidance raised; cash $281.2M at Sep 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000068/0001356576-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000068/supn-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer